Eysuvis®
Loteprednol Etabonate 0.25% · ophthalmic suspension
Dry Eye/OSD, Steroid
Approved uses
Signs and symptoms of dry eye disease, short-term (up to two weeks)
1 to 2 drops into each eye QID for up to 2 weeks
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
0.25% suspension (loteprednol etabonate 2.5 mg/mL), 8.3 mL in a 10 mL bottle
Corticosteroids inhibit inflammatory responses to many inciting agents and delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary and fibroblast proliferation, collagen deposition, and scar formation in inflammation. Glucocorticoids bind and activate their receptor, but how this modulates inflammation is not clearly established; they are thought to inhibit prostaglandin production. Lipid-soluble loteprednol etabonate is built from prednisolone-related compounds to change predictably to an inactive metabolite; preclinical studies show inactive carboxylic acid metabolites PJ-91 and PJ-90. After two drops four times daily for 14 days in 20 healthy adults, plasma levels were below the limit of quantitation (1 ng/mL). In animal models, mucus-penetrating particles gave 3.6-fold greater corneal penetration than traditional suspensions.
Warnings & Precautions
- Delayed healing and corneal perforation: Topical corticosteroids have been known to delay healing and cause corneal and scleral thinning; use over thin corneal or scleral tissue may lead to perforation. The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.
- IOP elevation and glaucoma: Prolonged corticosteroid use may produce glaucoma with optic nerve damage and defects in visual acuity and visual fields; use with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Secondary ocular infection: Corticosteroids may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions of the eye they may mask infection or enhance existing infection.
- Viral infection exacerbation: Ocular corticosteroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution.
- Fungal infections: Fungal corneal infection is particularly prone to develop coincidentally with long-term local corticosteroid use; consider fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use, and culture when appropriate.
- Contact lens wear: Remove lenses before instillation; the benzalkonium chloride 0.01% preservative may be absorbed by soft lenses, which may be reinserted 15 minutes after administration.
- Risk of contamination: Do not allow the dropper tip to touch any surface, as this may contaminate the suspension.
Common Side Effects
The most common adverse drug reaction following the use of EYSUVIS for two weeks was instillation site pain, which was reported in 5% of patients. Adverse reactions associated with ophthalmic corticosteroids include elevated intraocular pressure, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. In a pooled analysis of 4 randomized, vehicle-controlled trials that excluded subjects with a history of or current diagnosis of glaucoma, an IOP elevation (an increase from baseline of >5 mm Hg that resulted in an IOP of ≥21 mm Hg) occurred in 0.6% of subjects on the suspension and 0.2% on vehicle.
Pregnancy: No adequate and well controlled studies in pregnant women, and teratogenicity occurred at clinically relevant doses in rabbits and rats given the drug orally during pregnancy. Oral dosing in pregnant rabbits produced fetal malformations at 1.4 times the recommended human ophthalmic dose (spina bifida including meningocele), exencephaly and craniofacial malformations at 5.6 times, and abortion and embryofetal lethality at 83 times, with no developmental no-adverse-effect level established. Oral dosing in pregnant rats produced malformations at 34 times and embryofetal lethality at 695 times, with a developmental no-adverse-effect level of 3.4 times; in rats dosed from late gestation through lactation, survival of live-born offspring was reduced at 3.4 times. Background U.S. population risk is 2% to 4% for major birth defects and 15% to 20% for miscarriage.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production; weigh the developmental and health benefits of breastfeeding along with the mother's clinical need for EYSUVIS and any potential adverse effects on the breastfed infant from EYSUVIS.
Safety and effectiveness in pediatric patients have not been established.